Only in Titles

Search results for: Anti-Hepatitis B Surface Antigen (HBsAg) Antibody

paperclip

Error loading info... Pleas try again later.
paperclip

#31316835   2019/06/18 To Up

Antihepatitis B Surface Antigen and Hepatitis C Antibodies among Pregnant Women in an Urban Area of Mwanza City, Tanzania.

Hepatitis B and hepatitis C viruses (HBV and HCV) are life-threatening infections of public health importance due to their association with cirrhosis and hepatocellular carcinoma. Despite HBV being moderately endemic in many low-income countries, there is no routine HBV vaccination among child bearing aged women making them at risk of transmitting infections to the foetus during pregnancy. This study investigated the seroprevalence of antihepatitis B surface antibodies (anti-HBs) and HCV antibodies among pregnant women in Mwanza city to provide data that can be used in devising preventive strategies.
Elieza Chibwe, Vitus Silago, Edwin Kajoro, Muhsin Juma, Emmanuel Mkumbo, Caroline A Minja, Fridolin Mujuni, Stephen E Mshana, Mariam M Mirambo

1824 related Products with: Antihepatitis B Surface Antigen and Hepatitis C Antibodies among Pregnant Women in an Urban Area of Mwanza City, Tanzania.

100 μg2 Pieces/Box1 mL100ug/vial100 μg5ml1000 100ug100 100 μg1 mg2 Pieces/Box

Related Pathways

    No related Items
paperclip

#29895151   // To Up

Hepatitis B virus vaccine breakthrough infection: surveillance of S gene mutants of HBV.

Hepatitis B (HB) is a worldwide public health problem, closely related with liver cirrhosis and hepatocellular carcinoma (HCC). The implementation of universal hepatitis B virus (HBV) vaccination programs has led to significant reduction in incidence of acute and chronic HB, liver cirrhosis and HCC. However, this success is now being threatened by the discovery of HBV vaccine breakthrough infection caused by the S gene mutants of HBV, high maternal viral load and virus-induced immunosuppression. An alteration in the antigenicity and immunogenicity of hepatitis B surface antigen (HBsAg) due to S gene mutations may compromise detection of HBsAg (diagnosis-escape mutants), treatment with hepatitis B-specific immunoglobulin (HBIG), and even cause infections in individuals who are antihepatitis B surface antigen (anti-HBs) antibody-positive after immunization (vaccine-escape mutants). By surveilling for S gene mutants of HBV among vaccinated population, we will have a better understanding of the mechanism of HBV vaccine breakthrough infection; potentially providing new ideas for designing better diagnostic assays and effective vaccines for prevention and treatment of HBV. This review attempts to briefly summarize the status and role of S gene mutations, B-cell epitopes and T-cell epitope mutants, and surveillance of mutant HBV variants in a hospital setting.
Y Qin, P Liao

2300 related Products with: Hepatitis B virus vaccine breakthrough infection: surveillance of S gene mutants of HBV.

50 ug5ug2ug50 ug50 ug50 ug100ug Lyophilized100ug Lyophilized

Related Pathways

paperclip

Error loading info... Pleas try again later.
paperclip

Error loading info... Pleas try again later.
paperclip

#26879359   2016/02/15 To Up

Low Risk of Hepatitis B Virus Reactivation in HBsAg-negative/Anti-HBc-positive Carriers Receiving Rituximab for Rheumatoid Arthritis: A Retrospective Multicenter Italian Study.

Patients with resolved hepatitis B virus (HBV) infection, i.e., hepatitis B surface antigen (HBsAg)-negative/antihepatitis B core antigen (anti-HBc)-positive, undergoing rituximab (RTX)-based chemotherapy for hematological malignancies without anti-HBV prophylaxis are at risk of HBV reactivation, but the risk in such patients receiving RTX for rheumatological disorders is not clear. We evaluated this risk in HBsAg-negative/anti-HBc-positive patients with rheumatoid arthritis (RA) undergoing RTX without prophylaxis.
Valentina Varisco, Mauro Viganò, Alberto Batticciotto, Pietro Lampertico, Antonio Marchesoni, Patrizia Gibertini, Raffaele Pellerito, Guido Rovera, Roberto Caporali, Monica Todoerti, Michele Covelli, Antonella Notarnicola, Fabiola Atzeni, Piercarlo Sarzi-Puttini

1640 related Products with: Low Risk of Hepatitis B Virus Reactivation in HBsAg-negative/Anti-HBc-positive Carriers Receiving Rituximab for Rheumatoid Arthritis: A Retrospective Multicenter Italian Study.

100ug Lyophilized100ug Lyophilized100ug96T100ug Lyophilized100ug100ug100ug Lyophilized1 mL100ug Lyophilized100ug Lyophilized

Related Pathways

paperclip

#26015926   2015/05/11 To Up

Development of hen antihepatitis B antigen IgY-based conjugate for ELISA assay.

Chicken antibodies have many advantages to the mammalian antibodies and have several important differences against mammalian IgG with regard to their specificity and large-scale production. In this study, the production, purification, and HRP conjugation of polyclonal IgY against hepatitis virus surface antigen (HBsAg) were carried out.
Najat Muayed Nafea, Majeed Arsheed Sabbah, Raghad Al-Suhail, Amir Hossein Mahdavi, Sedigheh Asgary

1748 related Products with: Development of hen antihepatitis B antigen IgY-based conjugate for ELISA assay.

One 96-Well Microplate Ki0.1ml (1mg/ml)0.2 mg1 kit(96 Wells)0.1ml (1.3mg/ml)1 kit100 µgOne 96-Well Microplate KiTwo 96-Well Microplate KiOne 96-Well Microplate Ki0.1ml (1mg/ml)

Related Pathways

paperclip

#25894166   // To Up

Living-donor kidney transplant from hepatitis B surface antigen-positive donors to hepatitis B antibody-positive recipients without hepatitis B immunoglobulin prophylaxis in an endemic country.

Living-donor kidney transplant from donors who are chronically infected with hepatitis B virus can be considered as a possibility to compensate for insufficiency of organ transplants, particularly in a hepatitis B virus endemic country. In this study, the safety and efficacy were reviewed retrospectively in living-donor kidney transplant from donors who were chronically infected with hepatitis B virus.
Heungman Jun, Myung Gyu Kim, Kwan Tae Park, Cheol Woong Jung

2880 related Products with: Living-donor kidney transplant from hepatitis B surface antigen-positive donors to hepatitis B antibody-positive recipients without hepatitis B immunoglobulin prophylaxis in an endemic country.

100ug100ug Lyophilized100ug Lyophilized100 μg100μg100ug100ug 100ul100ug Lyophilized100ug100ug100ug

Related Pathways

paperclip

#27024910   // To Up

[Anti-hepatitis B vaccination and postvaccinal immunity stimulation in patients with chronic obstructive pulmonary disease].

The problem of the anti-hepatitis B vaccination of patients with chronic obstructive lung disease (COPD) was discussed due to the lack of studies concerning the developing of the postvaccinal immunity, especially when vaccination is combined with the immunomodulating treatment. The data on the vaccination safety and its influence on the clinical course of COPD are also insufficient. Therefore, in this work we investigated the efficiency of the antihepatitis B vaccination in adults with chronic obstructive pulmonary disease under the treatment with the immunomodulating Affonoleikin drug. A total of 93 patients were tested including 59 patients with severe and moderate COPD (aged from 35 to 65 years). 34 of these 59 patients were vaccinated against hepatitis B (Kombioteh) according to 0-1-6 month scheme, and 25 of them were vaccinated against hepatitis B during the treatment with Affinoleikin. The control group, consisted of 34 healthy patients. Our study demonstrated good tolerance and high immune efficiency of the anti-hepatitis B vaccine. However, after the first vaccination the level of HBs-AT was below protective level in patients with COPD compared to healthy patients. Also, 64 to 70 % of patients with COPD were seronegative excluding the patients receiving the Affinoleikin treatment, whose antibody titer was protective after the first vaccine dose, but did not reach the level typical of healthy patients. After the second vaccination we detected low and medium protective antibody levels in 58.9% of patients from the 1st group, whereas 41% were seronegative. Introduction of the third vaccine-dose led to fast and significant increase in the antibody level mainly in high concentrations with 100% seroconversion in all patients. Combined antihepatitis B vaccination and Affinoleikin treatment in patients with COPD leads to faster biosynthesis of HBs- AT in protective concentrations and decrease of seronegative response, but it has no effect on frequency and type of general and local postvaccinal response.
M P Kostinov, E Y Chikina, N A Kulakova, V N Borisova, O O Magarshak

2602 related Products with: [Anti-hepatitis B vaccination and postvaccinal immunity stimulation in patients with chronic obstructive pulmonary disease].

50 UG100ug Lyophilized100ug100ug100 100.00 ul100ug100ug

Related Pathways

paperclip

#25287829   2014/10/06 To Up

Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study.

Patterns of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen (HBsAg) -negative, antihepatitis B core antigen antibody (anti-HBc) -positive patients with lymphoma receiving rituximab-containing chemotherapy have not been well described.
Wai-Kay Seto, Thomas S Y Chan, Yu-Yan Hwang, Danny Ka-Ho Wong, James Fung, Kevin Sze-Hang Liu, Harinder Gill, Yuk-Fai Lam, Albert K W Lie, Ching-Lung Lai, Yok-Lam Kwong, Man-Fung Yuen

2172 related Products with: Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study.

100ug Lyophilized100ug Lyophilized100ug100ug Lyophilized100 ul 1 G100ug1 Set

Related Pathways